J. P. Benya
Directeur des opérations chez Flame Biosciences LLC
Postes actifs de J. P. Benya
Sociétés | Poste | Début | Fin |
---|---|---|---|
Flame Biosciences LLC
Flame Biosciences LLC Miscellaneous Commercial ServicesCommercial Services Flame Biosciences, Inc. operates as a biotechnology company. The firm offers research, development and commercialization of transformative therapies for cancer and other inflammatory conditions. The company was founded by Charles J. Fisher Jr., Patrick J. Scannon and Bob Stein and is headquartered in New York, NY. | Directeur des opérations | - | - |
Historique de carrière de J. P. Benya
Anciens postes connus de J. P. Benya
Sociétés | Poste | Début | Fin |
---|---|---|---|
ASSEMBLY BIOSCIENCES, INC. | Corporate Officer/Principal | 01/10/2012 | 01/12/2019 |
Transcept Pharmaceuticals, Inc. (Old)
Transcept Pharmaceuticals, Inc. (Old) Pharmaceuticals: MajorHealth Technology Transcept Pharmaceuticals, Inc. researches and develops biopharmaceutical products. The firm's products are used for pain, side effects of chemotherapy treatments, sleeplessness, and migraine headaches. Its drug delivery technology enhances absorption rates of active drug agents reduces absorption times. The company was founded in January, 2002 by Nikhilesh Singh and is headquartered in Pt. Richmond, CA. | Sales & Marketing | - | 03/02/2009 |
MEZZION PHARMA CO.,LTD. | Sales & Marketing | 01/01/2012 | - |
Ventrus Biosciences, Inc.
Ventrus Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Ventrus Biosciences, Inc. is a development stage specialty pharmaceutical company engages in development of late-stage prescription drugs for gastrointestinal disorders, specifically hemorrhoidal disease, anal fissures, and fecal incontinence. Its major pharmaceutical progress made in the gastrointestinal therapeutic areas of gastroesophageal reflux, peptic ulcer disease, and inflammatory bowel disease. Ventrus Biosciences products includes VEN 307 (topical diltiazem), is intended to treat pain associated with anal fissures and VEN 308 (topical phenylephrine), is intended to treat fecal incontinence. The company was founded on October 10, 2005 and is headquartered in New York, NY. | Corporate Officer/Principal | - | - |
Schering-Plough Corp.
Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ. | Sales & Marketing | - | - |
Formation de J. P. Benya
Brown University | Undergraduate Degree |
The Trustees of Columbia University in The City of New York | Masters Business Admin |
Statistiques
Internationale
Etats-Unis | 8 |
Corée du Sud | 2 |
Opérationnelle
Sales & Marketing | 3 |
Corporate Officer/Principal | 2 |
Undergraduate Degree | 1 |
Sectorielle
Health Technology | 6 |
Consumer Services | 3 |
Commercial Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 2 |
---|---|
MEZZION PHARMA CO.,LTD. | Health Technology |
ASSEMBLY BIOSCIENCES, INC. | Health Technology |
Entreprise privées | 4 |
---|---|
Transcept Pharmaceuticals, Inc. (Old)
Transcept Pharmaceuticals, Inc. (Old) Pharmaceuticals: MajorHealth Technology Transcept Pharmaceuticals, Inc. researches and develops biopharmaceutical products. The firm's products are used for pain, side effects of chemotherapy treatments, sleeplessness, and migraine headaches. Its drug delivery technology enhances absorption rates of active drug agents reduces absorption times. The company was founded in January, 2002 by Nikhilesh Singh and is headquartered in Pt. Richmond, CA. | Health Technology |
Schering-Plough Corp.
Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ. | Health Technology |
Ventrus Biosciences, Inc.
Ventrus Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Ventrus Biosciences, Inc. is a development stage specialty pharmaceutical company engages in development of late-stage prescription drugs for gastrointestinal disorders, specifically hemorrhoidal disease, anal fissures, and fecal incontinence. Its major pharmaceutical progress made in the gastrointestinal therapeutic areas of gastroesophageal reflux, peptic ulcer disease, and inflammatory bowel disease. Ventrus Biosciences products includes VEN 307 (topical diltiazem), is intended to treat pain associated with anal fissures and VEN 308 (topical phenylephrine), is intended to treat fecal incontinence. The company was founded on October 10, 2005 and is headquartered in New York, NY. | Health Technology |
Flame Biosciences LLC
Flame Biosciences LLC Miscellaneous Commercial ServicesCommercial Services Flame Biosciences, Inc. operates as a biotechnology company. The firm offers research, development and commercialization of transformative therapies for cancer and other inflammatory conditions. The company was founded by Charles J. Fisher Jr., Patrick J. Scannon and Bob Stein and is headquartered in New York, NY. | Commercial Services |
- Bourse
- Insiders
- J. P. Benya
- Expérience